NasdaqGS:ARQTBiotechs
Is It Time To Reassess Arcutis Biotherapeutics (ARQT) After A 96% One Year Rally?
If you are wondering whether Arcutis Biotherapeutics at US$26.65 is pricing in too much optimism or still leaving room on the table, the starting point is understanding what the market might already be expecting.
The share price return sits at 1.1% over the last 7 days, with a 9.1% decline over 30 days, an 8.1% decline year to date, but a 96.0% return over 1 year and 65.5% over 3 years, which suggests sentiment around risk and potential has shifted over different time frames.
Recent...